Annals of Oncology路 @Annals_Oncology 路 X路路 17 hours agoScore45
Body
馃摙 #ESMO26 concomitant paper: A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
馃敆https://shorturl.at/EHTHP
@Cecchini_OncMD
115 views 路 1 like 路 0 reposts 路 0 replies
Conference abstracts
2658ROmatched by Rapid oral 1: NSCLC, metastatic
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org791ROmatched by Rapid oral: Gastrointestinal tumours, lower digestive
Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.orgSource: Annals of Oncology 路 x.com